Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product candidate VP-102, is a proprietary topical therapy used in common skin indications including molluscum contagiosum and verruca vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verrica Pharmaceuticals reports strong Q3 revenue growth and promising therapies

Verrica Pharmaceuticals' Q3 performance reflects strong revenue generation from YCANTH and promising developments in novel therapies like VP-315.
While facing challenges in market clearance efforts and significant SG&A costs, the company's strategic initiatives position it for future growth.
Opportunities lie in expanding market presence, optimizing costs, and protecting intellectual property to drive profitability and innovation.

Verrica Pharmaceuticals reports robust Q4 earnings and eyes regulatory milestones

Verrica Pharmaceuticals showcased strong financial performance with $1.9 million in YCANTH net revenue and 94% gross margins for 2023.
Strategic partnerships, pipeline advancements, and progress in eliminating market challenges position the company for future growth.
Challenges in sampling activity, revenue forecasting, and regulatory uncertainties require careful navigation for sustained success.
Opportunities in distribution expansion, revenue optimization, and regulatory advancements offer avenues for continued development and success.

Verrica Pharmaceuticals excels in Q1 with strong revenue growth

Verrica Pharmaceuticals demonstrated strong performance in Q1 2024 with significant revenue generation and pipeline advancements.
While facing financial challenges and uncertainties, the company's strategic strengths and opportunities position it well for future growth.
Addressing cost management, market integrity, and maximizing revenue potential will be crucial for sustaining profitability and market leadership.

Verrica Pharmaceuticals excels in Q2, eyes market expansion opportunities

Verrica Pharmaceuticals' Q2 performance reflects strong revenue growth and promising developments in product pipelines. While challenges exist in accelerating demand and maintaining profitability, the company's strategic focus on partnerships and market optimization positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

SAN DIEGO & WEST CHESTER, Pa.--(BUSINESS WIRE)---- $VRCA #ClassAction--Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Verrica Pharmaceuticals Inc. (NYSE: VRCA) violated federal securities laws. Verrica is a clinical stage medical dermatology company that develops and commercializes dermatological treatments. If you suffered a loss as a result of Verrica's misconduct, click here. Verrica Pharmaceuticals Inc. (VRCA) Announces Receipt of FDA Letter On June

Shareholder Alert: Robbins LLP Announces It Is Investigating the Officers and Directors of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Shareholders

NEW YORK, July 2, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA). Investors who purchased Verrica securities are...

VRCA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 29, 2020, Verrica disclosed receipt of a letter from the U.S. Food and Drug Administration ("FDA") regarding the Company's New Drug Application

The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals (NASDAQ: VRCA) shares are trading lower on Tuesday. The company received a letter from the FDA regarding its VP-102 NDA indicating there are deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.

Why Verrica Pharmaceuticals Stock Is Trading Lower Today

WEST CHESTER, Pa., June  29, 2020  (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that, on June 24, 2020, the Company received a letter from the U.S. Food and Drug Administration (FDA) as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for VP-102 (cantharidin 0.7% topical solution), Verrica’s lead product candidate for the treatment of molluscum contagiosum. The letter states that there are deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter further states that the notification does not reflect a final decision on the information under review. In a letter dated November 26, 2019, the FDA had assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of July 13, 2020 for completion of its review of the NDA.

Verrica Pharmaceuticals Provides Regulatory Update on VP-102

- Pre-specified exploratory analysis showed VP-102 brought about a statistically significant percentage of patients with complete molluscum lesion clearance across all lesion count quartiles compared to vehicle -

Verrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum Contagiosum

–  Global biopharmaceutical industry veteran brings significant commercial expertise and business acumen to help advance the Company’s medical dermatology portfolio –

Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors

WEST CHESTER, Pa., March  11, 2020  (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that it has entered into a mezzanine loan and security agreement with Silicon Valley Bank (“SVB”) and WestRiver Innovation Lending Fund VIII, L.P., pursuant to which the lenders have agreed to lend the Company up to $50.0 million in a series of term loans. In addition, the Company entered into a loan and security agreement with SVB, pursuant to which SVB has agreed to provide the Company a revolving line of credit of up to $5.0 million.

Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley Bank

– Gerard DiGirolamo joins as Vice President, Sales,  and Sheila Kennedy joins as Vice President, Marketing –

Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial Capabilities

Verrica Pharmaceuticals Is An Undervalued Dermatology Player In 2020

Verrica's NDA Acceptance By FDA For VP-102 May Allow It To Enter Untapped Market

Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Sizing Up Verrica Pharmaceuticals

WEST CHESTER, Pa., Oct.  18, 2019  (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced the presentation of positive data from three abstracts evaluating the efficacy and safety of VP-102 (cantharidin 0.7% Topical Solution), the Company’s lead product candidate for the treatment of molluscum contagiosum and common warts. These data are being presented in poster form at the 2019 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV.

Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference

WEST CHESTER, Pa., Oct.  09, 2019  (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced it has appointed Eugene Scavola to the role of Executive Vice President, Technical Operations.

Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations

WEST CHESTER, Pa., Oct.  07, 2019  (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that the Company has appointed A. Brian Davis as its new Chief Financial Officer (CFO). Mr. Davis replaces Chris Degnan, who is leaving the organization to pursue an opportunity in the oncology sector.

Verrica Pharmaceuticals Announces Leadership Team Update

As of late, it has definitely been a great time to be an investor Verrica Pharmaceuticals.

Will Verrica Pharmaceuticals Continue to Surge Higher?

Galectin Therapeutics

Lannett Company

Zoetis

Small Drug Stock Outlook: Innovation Holds the Key to Growth

WEST CHESTER, Pa., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that Ted White, Verrica President and CEO, will present a business overview and review of the company’s pipeline programs at the H.C. Wainwright 21st Annual Global Investment Conference in New York, NY on Monday, September 9, 2019 at 3:00 p.m. ET.

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference

Verrica Pharmaceuticals obtains positive results from its phase 2 study using VP-102 to treat patients with common warts.

News for Verrica Pharmaceuticals Inc Stock (VRCA)